巴瑞替尼治疗难治性大动脉炎:一项三级转诊中心的前瞻性队列研究
这项前瞻性队列研究在三级转诊中心纳入10例难治性大动脉炎(TAK)患者,给予巴瑞替尼4 mg/日联合口服糖皮质激素。治疗6个月时,6/10(60%)获总体治疗反应;平均随访15.3个月期间,4/10(40%)维持总体治疗反应,1例因肝功能异常停用巴瑞替尼。作者认为巴瑞替尼4 mg/日对难治性TAK有效且耐受性良好。
要点
- 10例难治性TAK患者接受巴瑞替尼4 mg/日联合口服糖皮质激素,6个月时6/10(60%)达总体治疗反应。
- 平均随访15.3个月(范围4–31个月)期间,4/10(40%)维持总体治疗反应,8/10(80%)激素减量或维持原剂量。
- 1例因肝功能异常停用巴瑞替尼;2例分别在18个月和24个月停用激素并持续缓解至研究结束。
核心结论
- 作者认为巴瑞替尼4 mg/日对难治性大动脉炎有效且耐受性良好。
研究设计与样本
- 前瞻性队列研究,在三级转诊中心纳入10例难治性大动脉炎(TAK)患者,给予巴瑞替尼4 mg/日联合口服糖皮质激素(GCs)。
主要发现
- 纳入10例难治性TAK患者,中位年龄28岁(IQR=22–37),中位病程50个月(IQR=24–65),基线激素中位剂量为泼尼松或等效剂量10 mg(IQR=8.1–22.5)。
- 巴瑞替尼治疗6个月时,6/10(60%)患者达总体治疗反应。
- 平均随访15.3个月(范围4–31个月)期间,4/10(40%)患者维持总体治疗反应。
- 8/10(80%)患者在联合传统合成改善病情抗风湿药不变的情况下,激素减量或维持原剂量;2例分别在18个月和24个月停用激素,并持续缓解至研究结束。
- 1例因肝功能异常停用巴瑞替尼。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate the treatment efficacy and safety of baricitinib in patients with refractory Takayasu arteritis (TAK). METHODS: We performed a prospective cohort study in which baricitinib 4 mg daily was prescribed to patients with refractory TAK, combined with oral glucocorticoids (GCs). RESULTS: 10 patients with refractory TAK were enrolled with a median age of 28 (IQR=22-37) years, median disease duration of 50 (IQR=24-65) months. The median dose of GCs was 10 (IQR=8.1-22.5) mg prednisone or equivalence dosage at baseline. At 6 months of baricitinib treatment, 6/10 (60%) patients had an overall treatment response. During an average follow-up of 15.3 (range 4-31) months, 4/10 (40%) patients maintained overall treatment response. 8/10 (80%) patients tapered or maintained the same dose of GCs with no change of the combined classical synthetic disease-modifying antirheumatic drugs. Two patients discontinued GCs at 18 and 24 months and were in continuous remission till the end of the study. One patient withdrew baricitinib due to liver dysfunction. CONCLUSION: Baricitinib 4 mg daily is effective for refractory TAK and is well tolerated.
引用
- Zhou Z, Fang C, Wang L, et al. Baricitinib for refractory Takayasu arteritis: a prospective cohort study in a tertiary referral centre. RMD Open. 2024. PMID: 38519108. doi:10.1136/rmdopen-2023-003985
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。